YouTube video by Philip Jennelle

Undiagnosed PAVM amongst adult survivors of cryptogenic bacterial brain abscess is rare but may be considered in select patients. The prevalence of cardiac right-to-left shunts amongst brain abscess p...

The following companies are expected to report earnings prior to market open on 03/30/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Sigma Lithium Corporation (SGML)is reporting for the quarter ending December 31, 2025. The mining company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.12. This value represents a 50.00% decrease compared to the same quarter last year.

Lucid Diagnostics (LUCD) reported progress on multiple payment, billing, and coding pathways for its EsoGuard esophageal DNA test and EsoCheck cell collection device following three U.S. healthcare policy meetings in mid-September 2026.A Medicare Advisory Panel recommended maintaining EsoGuard’s original gapfill payment basis under the Clinical Laboratory Fee Schedule, with final CMS determinations expected in November after public comment. The AMA CPT Editorial Panel approved a new Category III CPT code for nonendoscopic esophageal cell collection procedures performed with EsoCheck. In addition, the ICD-10 Coordination and Maintenance Committee received a Lucid-backed proposal for diagnosis code R85.83 to report positive EsoGuard results, which the committee received positively and may finalize after comments.Lucid plans to begin submitting Medicare claims under PLA code 0114U from its Texas laboratory this month and from its California laboratory once a revised Local Coverage Determination becomes effective.

New peer-reviewed study validates EsoGuard's clinical impact with exceptional patient compliance and 100% provider referral rate for positive tests across 502 patients.

Click to view the official SEC document.

Click to view the official SEC document.

PAVmed (NASDAQ: PAVM) reported a second-quarter 2026 business update covering its subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health and Octeris Medical, along with financial results for the quarter ended June 30, 2026.Veris increased patient onboarding as its commercial engagement with OSU-The James advanced and continued development of its implantable physiological monitor toward a planned early 2027 FDA 510(k) submission. Lucid recognized $1.5 million in EsoGuard revenue on 2,770 tests, secured its first laboratory benefit manager coverage policy deeming EsoGuard medically necessary for eligible patients, and developed a cost-effectiveness model to support payor discussions.PAVmed highlighted PortIO first-in-human data showing 100% device patency, 90% completion of intended implant duration and no device-related adverse events, and ongoing FDA pre-submission work. Octeris advanced its multimodal endoscopic imaging probe toward clinical validation. For Q2 2026, PAVmed reported revenue of $33,000, operating expenses of $7.1 million, GAAP net loss attributable to common stockholders of approximately $5.5 million (or $(0.87) per diluted share), non-GAAP adjusted loss of $1.7 million, and cash of $3.8 million as of June 30, 2026.

Lucid Diagnostics (Nasdaq: LUCD) reported second quarter 2026 EsoGuard revenue of $1.474 million, up from $1.163 million in 2Q25, and processed 2,770 EsoGuard Esophageal DNA Tests. The company highlighted strengthening commercial activity, including its first laboratory benefit manager coverage policy via Concert, now part of Lyric, adopted by multiple client health plans.For the quarter ended June 30, 2026, Lucid recorded operating expenses of $14.3 million and a GAAP net loss of $11.7 million, with net loss attributable to common stockholders of $14.7 million, or $(0.08) per share. Non-GAAP adjusted loss was $10.9 million, or $(0.06) per share. Lucid held $33.4 million in cash and cash equivalents at June 30, 2026, compared with $34.7 million at December 31, 2025, and reported EBITDA of $(11.5) million. The company also developed a health economic cost-effectiveness model to support payor engagement for EsoGuard.

Lucid Diagnostics (Nasdaq: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive commercial coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer.The policy cites sufficient evidence in guidelines and peer-reviewed literature to demonstrate improved health outcomes and deems Lucid’s EsoGuard Esophageal DNA Test medically necessary for patients who meet American College of Gastroenterology (ACG) screening criteria. According to Lucid, multiple Concert client health plans have already adopted this policy, supporting broader commercial access to EsoGuard and reinforcing the company’s clinical evidence base.

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following...